Latest Hospitality News

Vitasora Health has secured approximately A$11 million in capital to accelerate its expansion in the US remote patient monitoring market, highlighted by an upgraded contract with TPAC covering 15,000 patients. The company targets a USD 18 million annual recurring revenue run-rate by late 2026.

EMVision Medical Devices has activated five of six pivotal trial sites for its emu™ bedside brain scanner, advancing towards FDA clearance while launching a parallel innovation study in Australia.

Echo IQ has initiated a pivotal clinical validation study with the Mayo Clinic Platform to test its EchoSolv HF software, marking the final step before its planned FDA submission in late 2025.

Orthocell Limited has posted a record quarterly revenue of A$2.73 million, driven by strong Australian sales of its nerve repair product Remplir™, with US market expansion poised to accelerate in FY26.

Optiscan Imaging Ltd has commenced a landmark clinical study at Royal Melbourne Hospital, testing its cutting-edge InVue® and InForm™ devices to improve breast cancer surgery precision. The study aims to generate critical data for US FDA approval and could redefine surgical oncology workflows.

The Star Entertainment Group updates investors on stalled negotiations with its joint venture partners over the Destination Brisbane Consortium transaction, facing a looming termination of their binding agreement.

Orthocell has marked a pivotal milestone with the first US surgical use of its Remplir™ nerve repair device following FDA clearance, setting the stage for commercial expansion in a $1.6 billion market.

HealthCo Healthcare & Wellness REIT reports a $1.483 billion portfolio valuation, down 4.3% due to cap rate shifts, while suspending its Q2 distribution to safeguard liquidity amid ongoing hospital asset due diligence.

Alcidion Group Limited has upgraded its full-year EBITDA guidance for FY25, now expecting earnings to exceed $4.5 million, driven by contract expansions, cost discipline, and favorable currency effects.

Emyria has landed a multi-year funding deal with Medibank to support its Empax PTSD program at Perth Clinic, marking a first for private insurer-backed psychotherapy in Australia. The company also announces a $4 million capital raise to fuel national expansion.

Artrya Limited has submitted a pivotal FDA 510(k) application for its AI-powered Salix® Coronary Plaque module, aiming for clearance in Q3 2025 and a lucrative US commercial launch.

EMVision Medical Devices has secured a $5 million non-dilutive government grant to accelerate global commercialisation of its innovative First Responder portable brain scanner, aimed at revolutionising pre-hospital stroke and brain injury care.